Topical Prodrug for Subcutaneous Fat Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for using adrenergic receptor agonists or antagonists to target subcutaneous fat tissue result in systemic concentrations that are too high, leading to significant side effects due to lack of specificity in delivery.
Innovation Solution
A pharmaceutical composition comprising a prodrug with a high octanol/water partition coefficient, specifically an ester form of an adrenergic receptor agonist or antagonist, for topical administration, which is hydrolyzed by endogenous enzymes in subcutaneous fat tissue to maintain high local concentrations without systemic absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adrenergic receptor agonists or antagonists are administered systemically to target subcutaneous fat tissue, then the therapeutic effect on fat tissue is achieved, but systemic concentrations become too high causing significant side effects
Solution Approach 1:
The patent segments the drug delivery system by creating a prodrug formulation that specifically targets subcutaneous fat tissue through topical application. The prodrug is designed to be hydrolyzed by lipases present in fat tissue, releasing the active adrenergic agent locally at the target site while minimizing systemic exposure. This spatial segmentation resolves the contradiction by concentrating the therapeutic effect where needed while avoiding harmful systemic concentrations.
Solution Approach 2:
The patent introduces a prodrug as an intermediary substance that mediates between the external application and the target adrenergic receptors in fat tissue. The prodrug itself has low adrenergic activity but is converted by lipases into the active adrenergic agonist or antagonist at the target site. This intermediary approach allows selective activation at the fat tissue level while avoiding systemic side effects of directly administering the active drug.
2Object-affected harmful factors
If topical administration is used to achieve local accumulation in subcutaneous fat tissue, then systemic absorption is avoided, but the prodrug must have specific lipophilic properties for effective penetration
Solution Approach 1:
The patent modifies the lipophilic parameters of the adrenergic agent by converting it into a prodrug with specific ester groups. This parameter change in molecular structure increases lipophilicity, enabling the prodrug to penetrate the stratum corneum and reach subcutaneous fat tissue through topical application. The specific lipophilic character is optimized to balance skin penetration capability with selective accumulation in fat tissue while avoiding systemic absorption.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The prodrug achieves a high affinity for subcutaneous fat tissue, allowing for localized modulation of fat tissue without systemic side effects, effectively shaping the body by increasing or decreasing fat tissue volume.
Implementation Method 1
the prodrug is hydrolyzed by the action of locally present endogenous enzymes, so that the adrenergic receptor agonist and/or the adrenergic receptor antagonist is released from the prodrug inside the subcutaneous fat tissue
Implementation Method 2
Enzymes which are capable of releasing the agonist or antagonist from the prodrug include for example lipase, esterase, paraoxonase, carboxylesterase, acetylcholinesterase, cholinesterase, biphenyl hydrolase, alkaline phosphatase, amidase, transpeptidase, CYP 450, trypsin, chymotrypsin, elastase, carboxypeptidase, aminopeptidase
Implementation Method 3
topical administration means that the prodrug is applied to the skin of a mammal, and penetrates the skin
Implementation Method 4
The absorption of the prodrug of the invention into the subcutaneous fat tissue results in an increased concentration of the agonist and/or antagonist in the local fat tissue
Data Source
Figure 1~2
Figure 3~4
Figure 5~6a
AI summary
The invention pertains to a pharmaceutical composition for topical administration, comprising a prodrug for an agonist and/or an antagonist for an adrenergic receptor, wherein the prodrug has an octanol/water partition coefficient of at least 0, for use in a method of shaping a mammalian body by modulation of subcutaneous fat tissue. The invention further pertains to cosmetic and therapeutic application of such prodrugs, such as their use in methods of shaping a mammalian body by locally modulating subcutaneous fat tissue. The invention also pertains to the prodrugs themselves, as well as to methods of making these prodrugs.